• Ilaria Frattale, Valeria Caponnetto, Alfonsina Casalena, Maurizio Assetta, Maurizio Maddestra, Fabio Marzoli, Giannapia Affaitati, Maria Adele Giamberardino, Stefano Viola, Amleto Gabriele, Francesca Pistoia, Davide Cerone, Carmine Marini, Simona Sacco, and Raffaele Ornello.
• Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Italy.
• J Headache Pain. 2021 Jan 6; 22 (1): 1.

BackgroundTriptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab.Main BodyIn our study, consecutive patients referring to the Headache Centers of the Abruzzo region from January 2019 to March 2020 and treated with erenumab were interviewed about past use and efficacy of triptans. Triptan users were classified as 'triptan responders' if they were headache-free 2 h after treating ≥3 migraine attacks with ≥1 triptan. We considered patients as 'erenumab responders', if they had a ≥ 50% mean reduction in monthly migraine days between the 4th and the 6th month from treatment start compared with baseline. Of 91 triptan users, 73 (80.2%) were triptan responders and 58 (63.7%) were erenumab responders. The odds ratio of being erenumab responder was 3.64 (95% CI, 1.25-10.64) for triptan users as compared to non-users. (P = 0.014). Besides, starting erenumab improved triptan response in both erenumab responders and non-responders.ConclusionsOur data of an association between response to triptans and response to erenumab can be useful for patient advice and to improve the understanding of migraine pathophysiology and treatment.

10 keywords...

hide…